An Australian Nobel Prize-winning scientist is developing a drug to counter allergies and asthma, a statement said on Friday.
Still in its initial stage the the drug can be taken as tablets, capsules, liquids or powder, Xinhua news reported.
Barry Marshall, a microbiology professor from University of Western Australia, who won the Nobel Prize in Physiology in 2005 for stomach ulcer research, is working on the new drug.
The medication, named Immbalance, aims to suppress an overactive immune system.
"This actually arose from work we were doing on helicobacter, the stomach bug, for which Robin Warren and I won the Nobel Prize a few years ago," Marshall said on Friday.
"We've discovered the way it survives in your body is by suppressing the immune system so you can't get rid of it.
"I can't guarantee that it's going to cure allergy sufferers... we think this kind of thing will bring people who are hyper reactive... down into the normal range."
Marshall, who spent the last seven years developing the drug, said that it can be formulated as tablets, capsules, liquids or powder.
"Children could spread the powder on their cereal or put it in a drink and over the course of a few months could suppress their allergic response," he said in a UWA media release.
"We think it's going to be 100 percent safe. It won't remove your immune system; it will just take the edge off."
--IANS
in/
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
